FDA-Approved Anti-Obesity Drugs in the United States

被引：121

作者：

Daneschvar, Homayoun L. ^{[1
]}

Aronson, Mark D. ^{[1
]}

Smetana, Gerald W. ^{[1
]}

机构：

[1] Harvard Med Sch, Div Gen Med & Primary Care, Beth Israel Deaconess Med Ctr, Shapiro 621C,330 Brookline Ave, Boston, MA 02215 USA

来源：

AMERICAN JOURNAL OF MEDICINE | 2016年 / 129卷 / 08期

关键词：

Anti-obesity drugs; Obesity; Weight loss; Weight loss drugs; PLACEBO-CONTROLLED TRIAL; CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE; WEIGHT-LOSS; SMOKING-CESSATION; OBESE ADULTS; DOUBLE-BLIND; OVERWEIGHT ADULTS; SUSTAINED-RELEASE; RANDOMIZED-TRIAL; EATING-DISORDER;

D O I：

10.1016/j.amjmed.2016.02.009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Obesity is a growing health problem in our society and its treatment has been challenging. In recent decades, several anti-obesity drugs have been withdrawn from the market because of reported and documented adverse effects. After years of interruption, the US Food and Drug Administration (FDA) has recently approved multiple new anti-obesity drugs. The majority of these medications are taken orally, and only one is administered subcutaneously. In this article, we review the efficacy, adverse effects, and mechanism of action of all 5 FDA-approved drugs. (C) 2016 Elsevier Inc. All rights reserved.

引用

页码：879.e1 / 879.e6

页数：6

共 41 条

[1] Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) [J].

Allison, David B. ;

Gadde, Kishore M. ;

Garvey, William Timothy ;

Peterson, Craig A. ;

Schwiers, Michael L. ;

Najarian, Thomas ;

Tam, Peter Y. ;

Troupin, Barbara ;

Day, Wesley W. .

OBESITY, 2012, 20 (02) :330-342

[2]

Antel J, 2012, HDB EXP PHARM, V209, P433, DOI DOI 10.1007/978-3-642-24716-3_

[3] A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II) [J].

Apovian, Caroline M. ;

Aronne, Louis ;

Rubino, Domenica ;

Still, Christopher ;

Wyatt, Holly ;

Burns, Colleen ;

Kim, Dennis ;

Dunayevich, Eduardo .

OBESITY, 2013, 21 (05) :935-943

[4]

ASHER WL, 1972, CURR THER RES CLIN E, V14, P525

[5] SUDDEN-DEATH ASSOCIATED WITH THYROID-HORMONE ABUSE [J].

BHASIN, S ;

WALLACE, W ;

LAWRENCE, JB ;

LESCH, M .

AMERICAN JOURNAL OF MEDICINE, 1981, 71 (05) :887-890

[6]

BLUNDELL JE, 1977, INT J OBESITY, V1, P15

[7] Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling [J].

Collins, BN ;

Wileyto, EP ;

Patterson, F ;

Rukstalis, M ;

Audrain-McGovern, J ;

Kaufmann, V ;

Pinto, A ;

Hawk, L ;

Niaura, R ;

Epstein, LH ;

Lerman, C .

NICOTINE & TOBACCO RESEARCH, 2004, 6 (01) :27-+

[8] Valvular heart disease associated with fenfluramine-phentermine [J].

Connolly, HM ;

Crary, JL ;

McGoon, MD ;

Hensrud, DD ;

Edwards, BS ;

Edwards, WD ;

Schaff, HV .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) :581-588

[9]

Counsel on Pharmacy and Chemistry, 1935, JAMA, V135, P31

[10] Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks [J].

Croft, H ;

Houser, TL ;

Jamerson, BA ;

Leadbetter, R ;

Bolden-Watson, C ;

Donahue, R ;

Metz, A .

CLINICAL THERAPEUTICS, 2002, 24 (04) :662-672

← 1 2 3 4 5 →